GLPG Stock Overview
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €32.95 |
52 Week High | €45.21 |
52 Week Low | €31.86 |
Beta | 0.027 |
1 Month Change | -9.73% |
3 Month Change | -19.06% |
1 Year Change | -12.44% |
3 Year Change | -57.26% |
5 Year Change | -73.10% |
Change since IPO | 319.75% |
Recent News & Updates
Recent updates
Galapagos: Pipeline Still Progressing Despite Financial Volatility
Mar 07Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product
Oct 10EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects
Oct 03Galapagos stock dips after Jefferies slashes rating citing challenges ahead
Jul 25Galapagos: Can The Company Turn Around?
May 19Galapagos: A History Of Disruptive Failures
Feb 22Galapagos: The Investment Thesis Is More Appealing Than Ever
Dec 02Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet
Jun 04Galapagos reports Q1 results
May 06Galapagos: Market Values Pipeline Below $0
Dec 30Galapagos candidate shows positive action in IPF proof-of-concept study
Nov 30Galapagos NV 2020 Q3 - Results - Earnings Call Presentation
Nov 06Galapagos Is A Buy Despite Setback In The U.S.
Oct 23Shareholder Returns
GLPG | US Biotechs | US Market | |
---|---|---|---|
7D | -3.0% | 0.9% | 0.4% |
1Y | -12.4% | 10.3% | 28.8% |
Return vs Industry: GLPG underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: GLPG underperformed the US Market which returned 29.5% over the past year.
Price Volatility
GLPG volatility | |
---|---|
GLPG Average Weekly Movement | 3.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GLPG's share price has been volatile over the past 3 months.
Volatility Over Time: GLPG's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 1,233 | Paul Stoffels | https://www.glpg.com |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.
Galapagos NV Fundamentals Summary
GLPG fundamental statistics | |
---|---|
Market cap | US$2.16b |
Earnings (TTM) | -US$4.32m |
Revenue (TTM) | US$259.53m |
8.3x
P/S Ratio-501.3x
P/E RatioIs GLPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GLPG income statement (TTM) | |
---|---|
Revenue | €239.72m |
Cost of Revenue | €241.29m |
Gross Profit | -€1.57m |
Other Expenses | €2.42m |
Earnings | -€3.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -0.061 |
Gross Margin | -0.65% |
Net Profit Margin | -1.66% |
Debt/Equity Ratio | 0% |
How did GLPG perform over the long term?
See historical performance and comparison